Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Harmony Biosciences Holdings, Inc. (HRMY) had Revenue of $200.49M for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$200.49M
Net Income	$39.78M
Cost of Goods Sold	$38.15M
Gross Profit	$162.34M
Operating Expenses	$152.31M
Operating Income	$48.18M
Non-Operating Income/Expense	$1.46M
Pre-Tax Income	$49.64M
Normalized Pre-Tax Income	$49.64M
Income after Taxes	$39.78M
Income from Continuous Operations	$39.78M
Consolidated Net Income/Loss	$39.78M
Normalized Income after Taxes	$39.78M
EBIT	$48.18M
EBITDA	$53.86M
Weighted-Average Shares Outstanding (Basic)	57.47M
Weighted-Average Shares Outstanding (Diluted)	58.43M
Earnings per Share (EPS) (Basic)	$0.69
Earnings per Share (EPS) (Diluted)	$0.68
Balance Sheet Financials
Current Assets	$691.35M
Property, Plant, and Equipment	$1.38M
Long-Term Assets	$416.65M
Total Assets	$1.11B
Current Liabilities	$180.13M
Long-Term Debt	$153.34M
Long-Term Liabilities	$154.79M
Total Liabilities	$334.93M
Common Equity	$773.08M
Tangible Shareholders Equity	$671.74M
Shareholders Equity	$773.08M
Common Shares Outstanding	57.54M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$113.31M
Cash Flow from Investing Activities	$-17.23M
Cash Flow from Financial Activities	$-3.04M
Beginning Cash	$453.27M
End Cash	$546.32M
Increase/Decrease in Cash	$93.05M
Stock-Based Compensation	$23.95M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.84
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.17
Debt to Equity Ratio	0.22
Gross Margin	80.97%
Operating Margin	24.03%
EBIT Margin	24.03%
EBITDA Margin	--
Pre-Tax Profit Margin	24.76%
Profit Margin	19.84%
Free Cash Flow	$113.18M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.18
Inventory Turnover	6.25
Receiveable Turnover	2.16
Days Sales in Receivables	41.74
Return on Equity	5.15%
Return on Tangible Equity	5.92%
Return on Assets	3.59%
Return on Investments	4.29%
Book Value Per Share	$13.44
Free Cash Flow per Share	$1.94
Operating Cash Flow per Share	$1.94

Data from Zacks Investment Research, Inc.